Boehringer Ingelheim India and NIPER Raebareli Sign MoU to Strengthen Pharmaceutical Education and Research Collaboration
Delhi, India – Business Wire India Boehringer Ingelheim India Private Limited today announced the signing of a Memorandum of Understanding (MoU) with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS). The MoU was signed at the Department of Pharmaceuticals in the presence of Shri Manoj Joshi, IAS, Secretary, Department of Pharmaceuticals.
Also present at the MoU signing ceremony were Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, Department of Pharmaceuticals, and Ms. Anugraha P, Director, Department of Pharmaceuticals.
The MoU establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange, and capability-building programmes.
As part of this MoU, Boehringer Ingelheim will support NIPER Raebareli by enabling access to opnMe®, which is Boehringer Ingelheim’s open science portal, designed to connect with researchers and institutions to accelerate scientific progress and enable innovation in healthcare. The partnership will also explore opportunities for symposia, conferences, short-term courses, and scholar engagement, helping strengthen learning, research, and scientific exchange.
Meenal Gauri, Managing Director, Boehringer Ingelheim India, said, “India is entering an important phase in its pharmaceutical journey, moving from scale-led growth to innovation-led impact. At Boehringer Ingelheim, we believe progress in healthcare is accelerated when industry, academia, and public institutions come together. This MoU with NIPER Raebareli reflects our commitment to strengthening scientific capability and supporting collaborations that can contribute to better health outcomes for patients and communities.” Prof. Shubhini A. Saraf, Director, NIPER Raebareli, added, “This MoU supports our vision of advancing pharmaceutical education and research while enabling opportunities for students and researchers to contribute to areas of emerging importance such as novel drug delivery systems and community health solutions. We look forward to working with Boehringer Ingelheim to create meaningful opportunities for students and researchers and to contribute to India’s innovation ecosystem.” India’s healthcare and innovation priorities are evolving rapidly. The Government of India is actively supporting the transition of the country’s pharmaceutical sector from being predominantly volume-driven and generic-led, to becoming a more innovation-led, high-value, and research-driven ecosystem, supported by policy focus, infrastructure development, and stronger industry-academia collaboration as part of the broader vision of Viksit Bharat 2047.
By strengthening the bridge between academic research and industry expertise, this partnership aims to contribute to the development of future-ready scientific talent and research pathways that can support more effective, accessible, and patient-centric healthcare solutions over time.
About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.
Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering innovative products in Human Pharma and Animal Health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. Learn more at https://www.boehringer-ingelheim.com/in.
More information boehringer-ingelheim.com To View the Image, Click on the Link Below: Boehringer Ingelheim & NIPER Raebareli sign MoU for advancing pharma research through strategic academic collaboration (Disclaimer: The above press release comes to you under an arrangement with Business Wire India and PTI takes no editorial responsibility for the same.).
(This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.)
